Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Table of Contents

What We're Reading

  • What We're Reading
    A Sampling of Highlights from the Literature
    Cancer Immunol Res July 1 2019 7 (7) 1037-1037;

Milestones in Cancer Immunology

  • Milestones in Cancer Immunology
    The Seventh Annual AACR-CRI Lloyd J. Old Award in Cancer Immunology
    Cancer Immunol Res July 1 2019 7 (7) 1038-1039; DOI:10.1158/2326-6066.CIR-19-0322

Cancer Immunology at the Crossroads

  • Cancer Immunology at the Crossroads | AuthorChoice
    Recharacterizing Tumor-Infiltrating Lymphocytes by Single-Cell RNA Sequencing
    Lei Zhang and Zemin Zhang
    Cancer Immunol Res July 1 2019 7 (7) 1040-1046; DOI:10.1158/2326-6066.CIR-18-0658

Cancer Immunology Miniatures

  • Cancer Immunology Miniatures
    BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy
    Eric L. Smith, Sham Mailankody, Mette Staehr, Xiuyan Wang, Brigitte Senechal, Terence J. Purdon, Anthony F. Daniyan, Mark B. Geyer, Aaron D. Goldberg, Elena Mead, Bianca D. Santomasso, Jonathan Landa, Andreas Rimner, Isabelle Riviere, Ola Landgren and Renier J. Brentjens
    Cancer Immunol Res July 1 2019 7 (7) 1047-1053; DOI:10.1158/2326-6066.CIR-18-0551

    Favorable response of advanced MM was seen in one patient given CAR T-cell therapy followed by localized radiation therapy. That TCR clonal expansion and CRS-like findings occurred after radiation therapy suggests synergy between these treatment modalities.

Research Articles

  • Research Articles
    RORγ Agonists Enhance the Sustained Antitumor Activity through Intrinsic Tc17 Cytotoxicity and Tc1 Recruitment
    Xikui Liu, Elizabeth M. Zawidzka, Hongxiu Li, Charles A. Lesch, Jenna Dunbar, Dick Bousley, Weiping Zou, Xiao Hu and Laura L. Carter
    Cancer Immunol Res July 1 2019 7 (7) 1054-1063; DOI:10.1158/2326-6066.CIR-18-0714

    Tumor evasion can ensue from too few infiltrating cytotoxic T cells—type 1 (Tc1) or 17 (Tc17)—or infiltration of dysfunctional effectors. RORγ agonists augmented Tc17 survival and lytic activity and directed recruitment of other functional effector cells.

  • Research Articles | AuthorChoice
    Targeting Hypoxia-Induced Carbonic Anhydrase IX Enhances Immune-Checkpoint Blockade Locally and Systemically
    Shawn C. Chafe, Paul C. McDonald, Saeed Saberi, Oksana Nemirovsky, Geetha Venkateswaran, Samantha Burugu, Dongxia Gao, Alberto Delaidelli, Alastair H. Kyle, Jennifer H.E. Baker, Jordan A. Gillespie, Ali Bashashati, Andrew I. Minchinton, Youwen Zhou, Sohrab P. Shah and Shoukat Dedhar
    Cancer Immunol Res July 1 2019 7 (7) 1064-1078; DOI:10.1158/2326-6066.CIR-18-0657

    The prognosis for breast cancer and melanoma patients is worse if their tumors metabolically regulate pH, promoting an acidic microenvironment, through enzymes like CAIX. Inhibition of CAIX plus blockade of immune checkpoints boosts antitumor responses by buffering acidosis.

  • Research Articles
    Hypoxia-Induced VISTA Promotes the Suppressive Function of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
    Jie Deng, Jiannan Li, Aurelien Sarde, J. Louise Lines, Yu-Chi Lee, David C. Qian, Dov A. Pechenick, Richard Manivanh, Isabelle Le Mercier, Christopher H. Lowrey, Frederick S. Varn, Chao Cheng, David A. Leib, Randolph J. Noelle and Rodwell Mabaera
    Cancer Immunol Res July 1 2019 7 (7) 1079-1090; DOI:10.1158/2326-6066.CIR-18-0507

    VISTA, induced on MDSCs by hypoxia in the tumor microenvironment, enhances suppression of both CD4+ and CD8+ T cells. This mechanism of hypoxia-driven immune escape and checkpoint resistance suggests a translatable approach to combination therapies.

  • Research Articles
    Tumor Cells Hijack Macrophage-Produced Complement C1q to Promote Tumor Growth
    Lubka T. Roumenina, Marie V. Daugan, Rémi Noé, Florent Petitprez, Yann A. Vano, Rafaël Sanchez-Salas, Etienne Becht, Julie Meilleroux, Bénédicte Le Clec'h, Nicolas A. Giraldo, Nicolas S. Merle, Cheng-Ming Sun, Virginie Verkarre, Pierre Validire, Janick Selves, Laetitia Lacroix, Olivier Delfour, Isabelle Vandenberghe, Celine Thuilliez, Sonia Keddani, Imene B. Sakhi, Eric Barret, Pierre Ferré, Nathalie Corvaïa, Alexandre Passioukov, Eric Chetaille, Marina Botto, Aurélien de Reynies, Stephane Marie Oudard, Arnaud Mejean, Xavier Cathelineau, Catherine Sautès-Fridman and Wolf H. Fridman
    Cancer Immunol Res July 1 2019 7 (7) 1091-1105; DOI:10.1158/2326-6066.CIR-18-0891

    The density of C1q-producing TAMs and C4d deposits, hallmarks of complement activation, are negative prognostic factors in human clear-cell renal cell carcinoma. Thus, the classical complement pathway is a potential therapeutic target for this cancer.

  • Research Articles | AuthorChoice
    Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia
    Yorleny Vicioso, Hermann Gram, Rose Beck, Abhishek Asthana, Keman Zhang, Derek P. Wong, John Letterio and Reshmi Parameswaran
    Cancer Immunol Res July 1 2019 7 (7) 1106-1119; DOI:10.1158/2326-6066.CIR-19-0058

    Blocking BAFF-R early in ALL promotes killing of leukemic cells. However, if given at later disease stages, efficacy is limited due to TGFβ. Combining VAY736 and a TGFβR1 inhibitor improved treatment efficacy in advanced and drug-resistant ALL.

  • Research Articles
    Inhibition of the NKp44-PCNA Immune Checkpoint Using a mAb to PCNA
    Kiran Kundu, Susmita Ghosh, Rhitajit Sarkar, Avishay Edri, Michael Brusilovsky, Orly Gershoni-Yahalom, Rami Yossef, Avishai Shemesh, Jean-Charles Soria, Vladimir Lazar, Ben-Zion Joshua, Kerry S. Campbell, Moshe Elkabets and Angel Porgador
    Cancer Immunol Res July 1 2019 7 (7) 1120-1134; DOI:10.1158/2326-6066.CIR-19-0023

    An immune checkpoint blocking antibody was developed against cancer cell surface PCNA, a ligand for NK-cell protein NKp44. Tests of the antibody in mice bearing patient-derived xenografts showed promise for overcoming tumor resistance to immunotherapy.

  • Research Articles
    Targeting the YB-1/PD-L1 Axis to Enhance Chemotherapy and Antitumor Immunity
    Zhen Tao, Hailong Ruan, Lin Sun, Dong Kuang, Yongchun Song, Qi Wang, Tao Wang, Yi Hao and Ke Chen
    Cancer Immunol Res July 1 2019 7 (7) 1135-1147; DOI:10.1158/2326-6066.CIR-18-0648

    The YB-1 signaling axis promotes tumor immune evasion and multidrug resistance. When targeted, chemoresistance decreased and antitumor responses were enhanced, suggesting an avenue for treating tumor multidrug resistance and immunosuppressive tumor microenvironments.

  • Research Articles
    Reduced Neoantigen Expression Revealed by Longitudinal Multiomics as a Possible Immune Evasion Mechanism in Glioma
    Takahide Nejo, Hirokazu Matsushita, Takahiro Karasaki, Masashi Nomura, Kuniaki Saito, Shota Tanaka, Shunsaku Takayanagi, Taijun Hana, Satoshi Takahashi, Yosuke Kitagawa, Tsukasa Koike, Yukari Kobayashi, Genta Nagae, Shogo Yamamoto, Hiroki Ueda, Kenji Tatsuno, Yoshitaka Narita, Motoo Nagane, Keisuke Ueki, Ryo Nishikawa, Hiroyuki Aburatani, Akitake Mukasa, Nobuhito Saito and Kazuhiro Kakimi
    Cancer Immunol Res July 1 2019 7 (7) 1148-1161; DOI:10.1158/2326-6066.CIR-18-0599

    Whole exome and RNA sequencing of paired primary and recurrent glioma specimens revealed decreased neoantigen expression at recurrence. Evidence of persistent immune responses suggests immune selection pressure as a possible mechanism, despite treatment with standard, nonimmune-based regimens.

  • Research Articles | AuthorChoice
    A Gene Signature Predicting Natural Killer Cell Infiltration and Improved Survival in Melanoma Patients
    Joseph Cursons, Fernando Souza-Fonseca-Guimaraes, Momeneh Foroutan, Ashley Anderson, Frédéric Hollande, Soroor Hediyeh-Zadeh, Andreas Behren, Nicholas D. Huntington and Melissa J. Davis
    Cancer Immunol Res July 1 2019 7 (7) 1162-1174; DOI:10.1158/2326-6066.CIR-18-0500

    Innate immunity can provide new targets for immunotherapy. Singscore, a gene-set scoring method, revealed that NK cell infiltration correlated with improved patient survival rates. Stromal and tumor elements, as well as cytokines involved in NK function were investigated.

  • Research Articles
    CCR4 Blockade Depletes Regulatory T Cells and Prolongs Survival in a Canine Model of Bladder Cancer
    Shingo Maeda, Kohei Murakami, Akiko Inoue, Tomohiro Yonezawa and Naoaki Matsuki
    Cancer Immunol Res July 1 2019 7 (7) 1175-1187; DOI:10.1158/2326-6066.CIR-18-0751

    Anti-CCR4 treatment to target regulatory T cells induced clinical responses and prolonged survival in dogs with spontaneous bladder cancer. Expression of CCR4 in human tumor samples suggests translational relevance for treatment of bladder cancer in humans.

  • Research Articles
    An Artificial Antigen-Presenting Cell Delivering 11 Immune Molecules Expands Tumor Antigen–Specific CTLs in Ex Vivo and In Vivo Murine Melanoma Models
    Lei Zhang, Shilong Song, Xiaoxiao Jin, Xin Wan, Khawar Ali Shahzad, Weiya Pei, Chen Zhao and Chuanlai Shen
    Cancer Immunol Res July 1 2019 7 (7) 1188-1201; DOI:10.1158/2326-6066.CIR-18-0881

    Multipotent microparticles bearing T-cell antigens and costimulatory molecules—and containing cytokines, chemokines, and checkpoint inhibitors—were injected intravenously into melanoma-bearing mice. These particles inhibited melanoma growth and expanded tumor-specific CTLs in peripheral blood, spleen, and tumor tissue.

  • Research Articles | AuthorChoice
    HPV Epitope Processing Differences Correlate with ERAP1 Allotype and Extent of CD8+ T-cell Tumor Infiltration in OPSCC
    Emma Reeves, Oliver Wood, Christian H. Ottensmeier, Emma V. King, Gareth J. Thomas, Tim Elliott and Edward James
    Cancer Immunol Res July 1 2019 7 (7) 1202-1213; DOI:10.1158/2326-6066.CIR-18-0498

    The ability to generate HPV-derived peptide antigens is governed by which ERAP1 molecules are expressed. Thus HPV+ OPSCC patients have different numbers of tumor-infiltrating CD8+ T cells, which affects disease progression.

  • Research Articles
    The Impact of High-Dose Glucocorticoids on the Outcome of Immune-Checkpoint Inhibitor–Related Thyroid Disorders
    Chanjuan Ma, F. Stephen Hodi, Anita Giobbie-Hurder, Xiaocheng Wang, Jing Zhou, Amy Zhang, Ying Zhou, Fei Mao, Trevor E. Angell, Chelsea P. Andrews, Jiani Hu, Romualdo Barroso-Sousa, Ursula B. Kaiser, Sara M. Tolaney and Le Min
    Cancer Immunol Res July 1 2019 7 (7) 1214-1220; DOI:10.1158/2326-6066.CIR-18-0613

    Thyroid disorders are common immune-related adverse events, and improved clinical management is needed. In this study, high dose glucocorticoids did not improve duration of thyrotoxicosis or onset of hypothyroidism in patients treated with immune checkpoint inhibitors.

Correction

  • Correction | Free Article
    Correction: Performance Evaluation of MHC Class-I Binding Prediction Tools Based on an Experimentally Validated MHC–Peptide Binding Data Set
    Cancer Immunol Res July 1 2019 7 (7) 1221-1221; DOI:10.1158/2326-6066.CIR-19-0387

Back to top
PreviousNext
Cancer Immunology Research: 7 (7)
July 2019
Volume 7, Issue 7
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

Jump to

  • What We're Reading
  • Milestones in Cancer Immunology
  • Cancer Immunology at the Crossroads
  • Cancer Immunology Miniatures
  • Research Articles
  • Correction
Advertisement
  • Most Cited
  • Most Read
Loading
  • Activity of Anti-CTLA-4 Isotypes in Antitumor Responses
  • Masters of Immunology
  • Extending Reach of Checkpoint Blockade in Pancreatic Cancer
  • PD-L1 in Triple-Negative Breast Cancer
  • Case Report: RNA CAR T Cells
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement